Greenwood Capital Associates LLC Sells 1,511 Shares of Bristol Myers Squibb Company $BMY

Greenwood Capital Associates LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,536 shares of the biopharmaceutical company’s stock after selling 1,511 shares during the period. Greenwood Capital Associates LLC’s holdings in Bristol Myers Squibb were worth $1,506,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Bristol Myers Squibb in the 1st quarter worth approximately $31,000. Accent Capital Management LLC bought a new stake in Bristol Myers Squibb during the 1st quarter valued at $33,000. CBIZ Investment Advisory Services LLC raised its holdings in Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in Bristol Myers Squibb during the 1st quarter valued at $36,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 1st quarter worth $37,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $45.75 on Friday. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The company’s 50-day moving average is $46.42 and its 200 day moving average is $48.76. The company has a market capitalization of $93.12 billion, a price-to-earnings ratio of 18.45, a price-to-earnings-growth ratio of 2.43 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 100.00%.

Analyst Ratings Changes

Several research analysts have commented on BMY shares. Citigroup decreased their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, August 1st. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Finally, Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $56.38.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.09% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.